Related Experiment Video

Updated: Apr 15, 2026

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

1.5K

A novel NGR-conjugated peptide targets DNA damage responses for radiosensitization

Jinlu Ma, Dan Zhang, Xia Ying

  • 1Department of Oncology, the First Affiliated Hospital of Xi'an Jiaotong University Medical College, Xi'an, Shaanxi 710061, China. shan87@mail.xjtu.edu.cn.

Current Cancer Drug Targets
|April 9, 2015
PubMed

Insights

A novel peptide, NGR-sR9-wtNIP, enhances radiotherapy effectiveness for liver cancer by improving radiosensitivity and inhibiting tumor growth. This peptide shows promise as a sensitizer for hepatocellular carcinoma treatment.

Area of Science:

  • Oncology
  • Radiotherapy
  • Molecular Biology

Background:

  • Hepatocellular carcinoma (HCC) has low intrinsic radiosensitivity, necessitating novel sensitizers for effective radiotherapy.
  • Wild-type NBS1 inhibitory peptide (wtNIP) enhances radiosensitivity by disrupting DNA damage response pathways.

Purpose of the Study:

  • To develop and evaluate a novel fusion peptide, NGR-sR9-wtNIP, for its radiosensitizing potential in hepatocellular carcinoma.
  • To assess the peptide's efficacy, tumor localization, and toxicity in preclinical models.

Main Methods:

  • Conjugation of CNGRC angiogenic vessel-homing peptide (NGR) with wtNIP to create NGR-sR9-wtNIP.
  • In vitro studies in Hep3B cells for internalization, cytotoxicity, and radiosensitization.
  • In vivo studies in nude mice with HCC xenografts to evaluate tumor localization, toxicity, and therapeutic efficacy when combined with irradiation.

Main Results:

  • NGR-sR9-wtNIP inhibited irradiation-induced NBS1 phosphorylation and demonstrated radiosensitizing effects in Hep3B cells.
  • The fusion peptide specifically localized to tumor tissues with minimal observed side effects in mice.
  • Combined treatment with NGR-sR9-wtNIP and irradiation significantly suppressed tumor growth in xenograft models.

Conclusions:

  • NGR-sR9-wtNIP exhibits significant radiosensitizing potential for hepatocellular carcinoma.
  • The targeted delivery and efficacy suggest NGR-sR9-wtNIP is a promising candidate for enhancing radiotherapy in HCC treatment.

More Related Videos

Single Molecule Analysis of Laser Localized Psoralen Adducts11:46

Single Molecule Analysis of Laser Localized Psoralen Adducts

Published on: April 20, 2017

7.2K
Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells05:18

Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells

Published on: June 9, 2020

12.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
46.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
70
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.4K
Nucleotide Excision Repair01:38

Nucleotide Excision Repair

DNA Distortion and Damage
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
5.9K
Nucleotide Excision Repair01:08

Nucleotide Excision Repair

Overview
42.8K